Cytosorbents (NASDAQ:CTSO) Earns “Neutral” Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has a $1.00 target price on the medical research company’s stock. HC Wainwright also issued estimates for Cytosorbents’ Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at ($0.30) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.14) EPS and FY2027 earnings at ($0.12) EPS.

Several other brokerages also recently issued reports on CTSO. StockNews.com began coverage on Cytosorbents in a report on Sunday, November 10th. They issued a “hold” rating for the company. EF Hutton Acquisition Co. I upgraded shares of Cytosorbents to a “strong-buy” rating in a report on Monday, July 29th.

Cytosorbents Stock Performance

Shares of NASDAQ:CTSO opened at $0.95 on Monday. The firm’s 50 day simple moving average is $1.13 and its 200 day simple moving average is $1.01. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $2.15. The company has a market capitalization of $51.94 million, a price-to-earnings ratio of -2.64 and a beta of 0.56. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.71.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings results on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The company had revenue of $9.89 million for the quarter, compared to analysts’ expectations of $9.73 million. During the same period last year, the firm posted ($0.14) earnings per share. As a group, sell-side analysts forecast that Cytosorbents will post -0.31 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of CTSO. CM Management LLC lifted its stake in Cytosorbents by 98.8% in the 1st quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock valued at $784,000 after acquiring an additional 410,000 shares in the last quarter. Avenir Corp lifted its position in shares of Cytosorbents by 4.0% in the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after purchasing an additional 121,294 shares in the last quarter. Sargent Investment Group LLC boosted its holdings in Cytosorbents by 4.9% during the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after purchasing an additional 67,181 shares during the last quarter. Finally, Atomi Financial Group Inc. bought a new position in Cytosorbents in the third quarter valued at $51,000. 32.87% of the stock is owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.